Sano Akihiko, Kato Hiroyuki, Sakurai Shinji, Sakai Makoto, Tanaka Naritaka, Inose Takanori, Saito Kana, Sohda Makoto, Nakajima Masanobu, Nakajima Takashi, Kuwano Hiroyuki
Department of General Surgical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
Ann Surg Oncol. 2009 Feb;16(2):506-14. doi: 10.1245/s10434-008-0252-0. Epub 2008 Dec 3.
Esophageal cancer is one of the most difficult malignancies to cure, and identification of novel prognostic markers for patients with this disease is important. CD24 is a small highly glycosylated mucin-like protein. Several studies have shown that higher CD24 expression is significantly associated with shorter patient survival in various malignant tumors. However, the expression of CD24 and its clinicopathological significance in esophageal cancer remain largely unknown. Immunohistochemical analyses of CD24 and Ki-67 overexpression in 151 cases of esophageal squamous cell carcinoma were performed to examine the relationships of CD24 expression with clinicopathological parameters and patient survival. Five cell lines derived from esophageal cancer were subjected to Western blot analyses to evaluate CD24 expression. Immunohistochemically, CD24 expression was judged to be positive in 61 (40.4%) cases. CD24 expression was associated with lymph node metastasis (p = 0.005), pathologic stage (p = 0.018), number of nodal metastases (p = 0.003), lymphatic invasion (p = 0.002), venous invasion (p < 0.001), and Ki-67 labeling index (p < 0.001). The Pearson's correlation coefficient between the CD24 expression score and the Ki-67 labeling index was 0.404 (p < 0.001). CD24 expression was associated with disease-free survival (p < 0.001). A Cox multivariate regression analysis revealed that CD24 expression was an independent prognostic factor (p = 0.033). On Western blot analysis, CD24 was detected in all five cell lines. We conclude that overexpression of CD24, which was correlated with Ki-67 expression, is a novel independent prognostic marker for identifying patients with poor prognosis after curative resection of esophageal squamous cell carcinoma.
食管癌是最难治愈的恶性肿瘤之一，因此为该病患者鉴定新的预后标志物非常重要。CD24是一种高度糖基化的小分子黏蛋白样蛋白。多项研究表明，在各种恶性肿瘤中，较高的CD24表达与患者较短的生存期显著相关。然而，CD24在食管癌中的表达及其临床病理意义在很大程度上仍不清楚。对151例食管鳞状细胞癌进行CD24和Ki-67过表达的免疫组织化学分析，以研究CD24表达与临床病理参数及患者生存期之间的关系。对5种源自食管癌的细胞系进行蛋白质免疫印迹分析，以评估CD24表达。免疫组织化学结果显示，61例（40.4%）病例的CD24表达为阳性。CD24表达与淋巴结转移（p = 0.005）、病理分期（p = 0.018）、淋巴结转移数量（p = 0.003）、淋巴管浸润（p = 0.002）、静脉浸润（p < 0.001）以及Ki-67标记指数（p < 0.001）相关。CD24表达评分与Ki-67标记指数之间的Pearson相关系数为0.404（p < 0.001）。CD24表达与无病生存期相关（p < 0.001）。Cox多因素回归分析显示，CD24表达是一个独立的预后因素（p = 0.033）。蛋白质免疫印迹分析检测到所有5种细胞系中均有CD24表达。我们得出结论，CD24过表达与Ki-67表达相关，是食管鳞状细胞癌根治性切除术后预后不良患者的一种新的独立预后标志物。
